A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 543, doi. 10.1007/s10637-006-9208-z
- Publication type:
- Article
Works matching IS 01676997 AND DT 2006 AND VI 24 AND IP 6
Results: 12
1
2
Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in rats.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 479, doi. 10.1007/s10637-006-6801-0
- Publication type:
- Article
3
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 515, doi. 10.1007/s10637-006-8440-x
- Publication type:
- Article
4
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 509, doi. 10.1007/s10637-006-9035-2
- Publication type:
- Article
5
Effects of the potential chemopreventive agent DMU-135 on adenoma development in the Apc<sup>Min+</sup> mouse.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 459, doi. 10.1007/s10637-006-5947-0
- Publication type:
- Article
6
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 537, doi. 10.1007/s10637-006-9244-8
- Publication type:
- Article
7
Antiangiogenic effect of 2-benzoyl–phenoxy acetamide in EAT cell is mediated by HIF-1α and down regulation of VEGF of in-vivo.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 471, doi. 10.1007/s10637-006-6587-0
- Publication type:
- Article
8
Studies on reaction of amino acids and triplet thioxanthone derivatives by laser flash photolysis.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 465, doi. 10.1007/s10637-006-7073-4
- Publication type:
- Article
9
A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 529, doi. 10.1007/s10637-006-9022-7
- Publication type:
- Article
10
MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 489, doi. 10.1007/s10637-006-7590-1
- Publication type:
- Article
11
Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 521, doi. 10.1007/s10637-006-8221-6
- Publication type:
- Article
12
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 6, p. 499, doi. 10.1007/s10637-006-8219-0
- Publication type:
- Article